Heron Therapeutics, Inc. — Q1 2015 Form 10-Q Summary
Reporting period: Three months ended March 31, 2015. The filing was dated May 8, 2015. Heron is a biotechnology company developing injectable therapies using its Biochronomer drug-delivery technology. Its principal programs were SUSTOL for chemotherapy-induced nausea and vomiting, HTX-011 for post-operative pain, HTX-019 for CINV, and HTX-003 for chronic pain and opioid addiction.
Financial Results and Position
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | No material operating revenue |
| Research and development expense | $14.5 million | $11.6 million | Up $2.9 million |
| General and administrative expense | $5.9 million | $5.7 million | Up $0.2 million |
| Total operating expenses | $20.4 million | $17.3 million | Up $3.0 million |
| Net loss | $20.6 million | $17.5 million | Loss increased $3.0 million |
| Basic and diluted loss per share | $0.70 | $0.74 | Improved due primarily to higher share count |
| Net cash used in operating activities | $19.7 million | $15.7 million | Use increased $4.0 million |
Cash and liquidity: Cash and cash equivalents were $55.6 million at March 31, 2015, down from $72.7 million at December 31, 2014. The quarterly cash decrease was $17.1 million, consisting principally of operating cash use of $19.7 million and capital expenditures of $0.3 million, partially offset by $2.9 million from stock-option exercises.
Balance sheet: Total assets were $59.6 million, current liabilities were $11.6 million, and stockholders’ equity was $48.0 million at March 31, 2015. The accumulated deficit was $335.8 million.
Debt: Convertible notes to related parties had a carrying value of $1.7 million, based on $5.4 million of principal less a $3.7 million debt discount. The notes bear 6% interest, mature in 2021, are secured by substantially all company assets, and holders may require prepayment at any time. Approximately 6.8 million shares would be issued if the principal amount were converted. Heron reported compliance with all note covenants.
Margins: Gross and operating margins are not meaningful because the company reported no revenue and all operating expenses were related to research, development, and administration.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 25% to $14.5 million, primarily because of clinical and manufacturing costs for the HTX-011 Phase 1 study and higher costs for the SUSTOL Phase 3 HEC study and related activities.
- General and administrative expense was broadly stable at $5.9 million versus $5.7 million.
- Net loss increased to $20.6 million from $17.5 million, while loss per share declined to $0.70 from $0.74 because weighted-average shares increased to 29.4 million from 23.7 million.
- Operating cash use increased to $19.7 million from $15.7 million, and cash at quarter-end was below the March 31, 2014 balance of $57.5 million.
- Stock-based compensation decreased to $2.6 million from $3.0 million. At March 31, 2015, $29.9 million of unrecognized compensation cost remained, expected to be recognized over a weighted-average period of 2.4 years.
- Heron Therapeutics B.V., a wholly owned Netherlands subsidiary formed in March 2015, had no operations and no material assets or liabilities.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that existing working capital was expected to fund operations through 2015, including SUSTOL regulatory activities, HTX-011 development, and HTX-019 clinical and preclinical work.
- Heron completed enrollment in the SUSTOL Phase 3 HEC study in April 2015 and anticipated resubmitting the SUSTOL NDA around mid-2015, including the HEC study results. SUSTOL had previously received Complete Response Letters in 2010 and 2013 involving dosing-system, CMC, manufacturing, human-factors, and clinical-data issues.
- HTX-011 completed a Phase 1 study in March 2015. Management reported a desired pharmacokinetic profile, anesthetic effects through 96 hours, and no serious adverse events, and planned to begin Phase 2 development in the second quarter of 2015.
- Management stated that additional capital would be required if the company expanded clinical development, acquired strategic assets, or made significant commercialization investments. Heron had no current means of generating material operating cash flow and warned that additional financing might not be available on acceptable terms or at all.
- Key risks include clinical-trial results, FDA approval and timing, manufacturing and supply constraints, contract-manufacturer deficiencies, commercialization costs and acceptance, patent protection, vendor and collaboration relationships, and the need for additional financing.
- Contractual obligations disclosed consisted of $1.3 million of operating lease payments, including $0.8 million due within one year. Clinical-site and contract-research-organization commitments were variable and could include termination penalties; future amounts were not estimable with certainty.
- The company reported no legal proceedings, no off-balance-sheet arrangements, and no material changes to internal control over financial reporting. Disclosure controls were assessed as effective at the reasonable-assurance level.
- ASU 2015-01 was adopted in the first quarter of 2015 and had no material effect on results or financial condition.
Investor Verification Checklist
- Verify the results and regulatory implications of the SUSTOL HEC study and the timing, completeness, and FDA response to the planned NDA resubmission.
- Assess whether the $55.6 million cash balance and projected cash burn were sufficient beyond 2015, particularly if commercialization or expanded clinical programs proceeded.
- Review the terms and prepayment rights of the secured convertible notes, including potential dilution from approximately 6.8 million underlying shares.
- Monitor HTX-011 Phase 2 initiation, clinical results, safety findings, and development costs.
- Evaluate manufacturing, CMC, human-factors, supply, and contract-manufacturer risks that previously contributed to SUSTOL Complete Response Letters.
- Track quarterly operating cash burn, research and development spending, equity financing needs, and potential dilution.